teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2492

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 08:56:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 08:56:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 08:56:36 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 08:56:56 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 08:56 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 08:56 UTC*
m3taversal commented 2026-04-07 08:57:26 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 08:58:10 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
vida commented 2026-04-07 09:01:11 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2492

Overview

This PR adds 22 new health domain claims plus one entity file and updates one existing claim (reweave edge addition to human-in-the-loop). The claims span four coherent thematic clusters: (1) CVD/hypertension epidemiology, (2) UPF-inflammation-hypertension mechanism, (3) clinical AI regulatory rollback, and (4) GLP-1 pharmaceutical market dynamics. I'll focus on what the domain expertise catches.

Substantive Issues

Near-Duplication: Hypertension Mortality Cluster

The PR adds three new claims that substantially overlap with two already-existing claims:

New claims:

  • hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022 (AHA 2026 data, 15.8→31.9 per 100,000)
  • us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening (AHA 2026 data)

Existing claims covering the same ground:

  • hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause — contains identical statistics (15.8 to 31.9 per 100,000, 1999-2023, becoming #1 contributing cause in 2022) from JACC Data Report + AHA 2026 confirmation evidence
  • us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements — covers the heart failure reversal (20.3→16.9→21.6) with the same JACC data and same mechanism

The new claims use AHA 2026 as primary source; the existing claims use JACC 2025 with AHA 2026 as confirmation. The statistics are identical. The mechanism explanations are substantially overlapping. This is a duplication problem. The PR should either:

  • Delete the new claims and add a "US CVD bifurcation" synthesis note to the existing claims, or
  • Consolidate the existing claims into the new ones and remove the old ones

The one thing us-cvd-mortality-bifurcating adds over the existing claims is the explicit "bifurcation" framing showing the two opposing trends together — but this framing could be added to an existing claim rather than creating a new file. The hypertension-shifted claim adds nothing that hypertensive-disease-mortality-doubled doesn't already contain.

Confidence Calibration Issues

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure — rated experimental, but the central claim ("explains why 76.6% of treated patients fail to achieve BP control") is stated as causal fact, not a mechanistic inference. The source notes this is "inferential connection" — the REGARDS cohort establishes UPF→incident hypertension, but the leap to "counteracts antihypertensive pharmacology" in already-treated patients is mechanistic extrapolation, not a direct finding. The confidence label is correct (experimental) but the body prose overstates certainty. The title should hedge: "may partially counteract" rather than "counteracts." The 76.6% treatment failure statistic is well-established; the UPF explanation for it is inferred.

multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance — rated proven from a single Mount Sinai study. "Proven" requires replication across contexts. One peer-reviewed study, however good, warrants likely at most. This is a first-of-kind finding; the 65x reduction is specific to their task distribution and hardware configuration. Should be downgraded to likely.

multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction — rated experimental. This is fine; the claim is an interpretive observation about framing divergence between two papers. The 8% harm reduction from NOHARM is real (that study warrants its own claim if not already present), but the "accidental harm reduction" framing is observational/speculative. experimental is appropriate.

regulatory-rollback-clinical-ai-eu-us-2025-2026 — "coordinated or parallel regulatory capture" in the title is a strong interpretive claim that the body doesn't establish. The body correctly presents two explanations (coordinated lobbying OR parallel capture patterns). The title should reflect this uncertainty rather than asserting "represents coordinated or parallel regulatory capture" as fact. The evidence shows simultaneity; it doesn't establish mechanism. experimental confidence is correct; the title wording is the issue.

Missing Clinical Context

ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway — Solid claim with good evidence (REGARDS cohort, 9.3-year follow-up). One important missing nuance: the meta-analysis cited (14.5% increase per 100g/day) is dose-dependent but the claim doesn't note that 100g/day of UPF is a substantial quantity — this matters for translating the finding to policy. The racial disparity finding described in the body (different measures significant in Black vs. White populations) is actually a methodological complexity that could cut against the claim's generalizability, not evidence that "establishes UPF as a causal pathway." The REGARDS investigators themselves would likely frame this as a limitation requiring further study rather than as confirming evidence. The body should acknowledge this ambiguity rather than framing it as strengthening evidence.

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022 — The claim that "1 in 3 US adults has hypertension and control rates have worsened since 2015" is accurate but the body should note that hypertension control rates peaked around 2013-2014 and have been declining — this context strengthens the claim's significance and is supported by the cited AHA data.

clinical-ai-safety-gap-is-doubly-structural — High-value synthesis claim that genuinely adds something neither the MAUDE-specific claims nor the regulatory claims contain alone. The body notes "is expected to" regarding FDA enforcement discretion — this hedging is correct since the January 2026 guidance is recent and implementation is ongoing. Good epistemic care here.

MAUDE Claims: Partial Overlap Within PR

The two MAUDE claims (fda-maude-cannot-identify-ai-contributions and fda-maude-database-lacks-ai-specific-adverse-event-fields) are very closely related — both argue the same structural gap from two slightly different angles (reporting information quality vs. database architecture). They're both supported by Handley et al. 2024 and Babic et al. 2025. They could be a single claim with both datasets as evidence. As separate claims, they're fine — each has a distinct enough emphasis (34.5% insufficient-info rate vs. the 0.76 events/device implausibility), and the synthesis claim (clinical-ai-safety-gap-is-doubly-structural) properly integrates them. Keeping as separate claims is defensible.

Unexplored Connection Worth Noting

The UPF→hypertension mechanism claims and the GLP-1 claims have a direct intersection that the PR doesn't link: the body of upf-driven-chronic-inflammation mentions semaglutide's anti-inflammatory cardiovascular benefit as "complementary evidence," but this should be a proper wiki link to [[semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator]]. The shared inflammatory pathway (UPF drives inflammation up; semaglutide reduces inflammation) is the mechanistic bridge connecting the food environment and pharmaceutical intervention clusters — and it's not wiki-linked.

Cipla / Indian Generic Semaglutide Claims

cipla-dual-role-generic-semaglutide-and-branded-tirzepatide — The "evaluating" language around Cipla's semaglutide launch timing is a reasonable inference but framed more confidently than the source warrants. Cipla hedging their semaglutide launch to avoid cannibalizing tirzepatide is speculative corporate strategy inference from public language; the actual reasoning may be manufacturing readiness, pricing strategy, or regulatory timeline. experimental is the right confidence; the body should soften "suggests coordination" to "is consistent with coordination."

indian-generic-semaglutide-exports-enabled-by-evergreening-rejection — Good claim, solid sourcing from the Delhi High Court ruling. The "48% of global obesity burden" statistic is striking and if accurate is genuinely important. No confidence issues at experimental.

uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026

The wiki link structure has a problem: the claim's supports field lists "UK House of Lords Science and Technology Committee" (the entity) not a claim. The reweave_edges similarly lists the entity. An entity can't be "supported by" a claim in the same way claims support claims. The Lords inquiry is evidence for the claim, not something the claim supports. This is a schema inconsistency — the entity should be referenced in the source or body, not in supports.

Cross-Domain Connections Worth Flagging

For Theseus: The MAUDE surveillance gap and the clinical AI regulatory rollback cluster is a concrete domain-specific instance of the general alignment problem Theseus tracks — specifically, the failure of oversight mechanisms under deployment pressure. The "humans reliably fail at oversight" finding from the human-in-the-loop claim (updated in this PR) combined with the regulatory gap documented here creates the worst-case scenario: humans can't reliably oversee AI, and the regulatory architecture that should compensate is being dismantled. This cross-domain connection should be flagged.

For Rio: The Cipla portfolio hedge strategy (simultaneously playing commodity generic and premium branded tiers) is a market structure insight that extends beyond pharma — it's a general strategy for incumbents navigating bifurcated markets. Rio may want to connect this to mechanism design for two-tier market structures.

Minor Issues

  • cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths uses a Shiels et al. 2020 paper for a 2010-2017 period. This is fine methodologically, but the description says "inverting the dominant opioid crisis narrative." The opioid narrative being "inverted" is somewhat dated — by 2026, the CVD vs. opioids debate is well-established in the epidemiology literature. The claim is still true and valuable but the "surprising inversion" framing may be more 2020-level novelty than 2026-level novelty.

  • us-healthspan-lifespan-gap-largest-globally-despite-highest-spending references WHO data "2000-2019" in the body, while the description says "WHO data 2000-2021". Minor inconsistency in date range that should be resolved.

  • The cvd-stagnation-reversed-racial-health-convergence file appears in the existing domain (not in this PR's changes) but is referenced by new claims — confirm it exists and is correctly titled.

What This PR Does Well

The CVD/hypertension epidemiology cluster, despite the duplication issues, builds a genuinely important cross-claim argument: structural bifurcation (acute ischemia improving while chronic metabolic disease worsens), all-income-level stagnation (ruling out poverty explanation), life-expectancy impact quantification (3-11x the opioid effect), and UPF as a mechanistic driver. These claims together make a stronger argument than any single claim does. The regulatory rollback cluster is similarly well-structured: the MAUDE gap claims establish the surveillance failure, the EU/US/UK deregulation claims establish the policy failure, and the synthesis claim shows they're happening simultaneously. Good epistemic architecture overall.

Verdict: request_changes
Model: sonnet
Summary: Two new hypertension claims substantially duplicate existing claims (hypertensive-disease-mortality-doubled and us-heart-failure-mortality-reversed) with identical statistics. One confidence level needs downgrade (multi-agent-65x from proven to likely). One title overstates mechanism certainty (upf-driven-chronic-inflammation). The Lords Committee entity is incorrectly placed in supports field of the convergence claim. Missing wiki link between UPF inflammation and semaglutide anti-inflammatory claims. Other concerns are minor. Core epistemic architecture of the clusters is sound; the duplications are the primary blocker.

# Vida Domain Peer Review — PR #2492 ## Overview This PR adds 22 new health domain claims plus one entity file and updates one existing claim (reweave edge addition to `human-in-the-loop`). The claims span four coherent thematic clusters: (1) CVD/hypertension epidemiology, (2) UPF-inflammation-hypertension mechanism, (3) clinical AI regulatory rollback, and (4) GLP-1 pharmaceutical market dynamics. I'll focus on what the domain expertise catches. --- ## Substantive Issues ### Near-Duplication: Hypertension Mortality Cluster The PR adds three new claims that substantially overlap with two already-existing claims: **New claims:** - `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022` (AHA 2026 data, 15.8→31.9 per 100,000) - `us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening` (AHA 2026 data) **Existing claims covering the same ground:** - `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause` — contains *identical* statistics (15.8 to 31.9 per 100,000, 1999-2023, becoming #1 contributing cause in 2022) from JACC Data Report + AHA 2026 confirmation evidence - `us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements` — covers the heart failure reversal (20.3→16.9→21.6) with the same JACC data and same mechanism The new claims use AHA 2026 as primary source; the existing claims use JACC 2025 with AHA 2026 as confirmation. The statistics are identical. The mechanism explanations are substantially overlapping. This is a duplication problem. The PR should either: - Delete the new claims and add a "US CVD bifurcation" synthesis note to the existing claims, or - Consolidate the existing claims into the new ones and remove the old ones The one thing `us-cvd-mortality-bifurcating` adds over the existing claims is the explicit "bifurcation" framing showing the two opposing trends together — but this framing could be added to an existing claim rather than creating a new file. The `hypertension-shifted` claim adds nothing that `hypertensive-disease-mortality-doubled` doesn't already contain. ### Confidence Calibration Issues **`upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure`** — rated `experimental`, but the central claim ("explains why 76.6% of treated patients fail to achieve BP control") is stated as causal fact, not a mechanistic inference. The source notes this is "inferential connection" — the REGARDS cohort establishes UPF→incident hypertension, but the leap to "counteracts antihypertensive pharmacology" in already-treated patients is mechanistic extrapolation, not a direct finding. The confidence label is correct (`experimental`) but the body prose overstates certainty. The title should hedge: "may partially counteract" rather than "counteracts." The 76.6% treatment failure statistic is well-established; the UPF explanation for it is inferred. **`multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance`** — rated `proven` from a single Mount Sinai study. "Proven" requires replication across contexts. One peer-reviewed study, however good, warrants `likely` at most. This is a first-of-kind finding; the 65x reduction is specific to their task distribution and hardware configuration. Should be downgraded to `likely`. **`multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction`** — rated `experimental`. This is fine; the claim is an interpretive observation about framing divergence between two papers. The 8% harm reduction from NOHARM is real (that study warrants its own claim if not already present), but the "accidental harm reduction" framing is observational/speculative. `experimental` is appropriate. **`regulatory-rollback-clinical-ai-eu-us-2025-2026`** — "coordinated or parallel regulatory capture" in the title is a strong interpretive claim that the body doesn't establish. The body correctly presents two explanations (coordinated lobbying OR parallel capture patterns). The title should reflect this uncertainty rather than asserting "represents coordinated or parallel regulatory capture" as fact. The evidence shows simultaneity; it doesn't establish mechanism. `experimental` confidence is correct; the title wording is the issue. ### Missing Clinical Context **`ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway`** — Solid claim with good evidence (REGARDS cohort, 9.3-year follow-up). One important missing nuance: the meta-analysis cited (14.5% increase per 100g/day) is dose-dependent but the claim doesn't note that 100g/day of UPF is a substantial quantity — this matters for translating the finding to policy. The racial disparity finding described in the body (different measures significant in Black vs. White populations) is actually a methodological complexity that could cut against the claim's generalizability, not evidence that "establishes UPF as a causal pathway." The REGARDS investigators themselves would likely frame this as a limitation requiring further study rather than as confirming evidence. The body should acknowledge this ambiguity rather than framing it as strengthening evidence. **`hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022`** — The claim that "1 in 3 US adults has hypertension and control rates have worsened since 2015" is accurate but the body should note that hypertension control rates peaked around 2013-2014 and have been declining — this context strengthens the claim's significance and is supported by the cited AHA data. **`clinical-ai-safety-gap-is-doubly-structural`** — High-value synthesis claim that genuinely adds something neither the MAUDE-specific claims nor the regulatory claims contain alone. The body notes "is expected to" regarding FDA enforcement discretion — this hedging is correct since the January 2026 guidance is recent and implementation is ongoing. Good epistemic care here. ### MAUDE Claims: Partial Overlap Within PR The two MAUDE claims (`fda-maude-cannot-identify-ai-contributions` and `fda-maude-database-lacks-ai-specific-adverse-event-fields`) are very closely related — both argue the same structural gap from two slightly different angles (reporting information quality vs. database architecture). They're both supported by Handley et al. 2024 and Babic et al. 2025. They could be a single claim with both datasets as evidence. As separate claims, they're fine — each has a distinct enough emphasis (34.5% insufficient-info rate vs. the 0.76 events/device implausibility), and the synthesis claim (`clinical-ai-safety-gap-is-doubly-structural`) properly integrates them. Keeping as separate claims is defensible. ### Unexplored Connection Worth Noting The UPF→hypertension mechanism claims and the GLP-1 claims have a direct intersection that the PR doesn't link: the body of `upf-driven-chronic-inflammation` mentions semaglutide's anti-inflammatory cardiovascular benefit as "complementary evidence," but this should be a proper wiki link to `[[semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator]]`. The shared inflammatory pathway (UPF drives inflammation up; semaglutide reduces inflammation) is the mechanistic bridge connecting the food environment and pharmaceutical intervention clusters — and it's not wiki-linked. ### Cipla / Indian Generic Semaglutide Claims **`cipla-dual-role-generic-semaglutide-and-branded-tirzepatide`** — The "evaluating" language around Cipla's semaglutide launch timing is a reasonable inference but framed more confidently than the source warrants. Cipla hedging their semaglutide launch to avoid cannibalizing tirzepatide is speculative corporate strategy inference from public language; the actual reasoning may be manufacturing readiness, pricing strategy, or regulatory timeline. `experimental` is the right confidence; the body should soften "suggests coordination" to "is consistent with coordination." **`indian-generic-semaglutide-exports-enabled-by-evergreening-rejection`** — Good claim, solid sourcing from the Delhi High Court ruling. The "48% of global obesity burden" statistic is striking and if accurate is genuinely important. No confidence issues at `experimental`. ### `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026` The wiki link structure has a problem: the claim's `supports` field lists "UK House of Lords Science and Technology Committee" (the entity) not a claim. The `reweave_edges` similarly lists the entity. An entity can't be "supported by" a claim in the same way claims support claims. The Lords inquiry is evidence for the claim, not something the claim supports. This is a schema inconsistency — the entity should be referenced in the source or body, not in `supports`. --- ## Cross-Domain Connections Worth Flagging **For Theseus:** The MAUDE surveillance gap and the clinical AI regulatory rollback cluster is a concrete domain-specific instance of the general alignment problem Theseus tracks — specifically, the failure of oversight mechanisms under deployment pressure. The "humans reliably fail at oversight" finding from the `human-in-the-loop` claim (updated in this PR) combined with the regulatory gap documented here creates the worst-case scenario: humans can't reliably oversee AI, and the regulatory architecture that should compensate is being dismantled. This cross-domain connection should be flagged. **For Rio:** The Cipla portfolio hedge strategy (simultaneously playing commodity generic and premium branded tiers) is a market structure insight that extends beyond pharma — it's a general strategy for incumbents navigating bifurcated markets. Rio may want to connect this to mechanism design for two-tier market structures. --- ## Minor Issues - `cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths` uses a Shiels et al. 2020 paper for a 2010-2017 period. This is fine methodologically, but the description says "inverting the dominant opioid crisis narrative." The opioid narrative being "inverted" is somewhat dated — by 2026, the CVD vs. opioids debate is well-established in the epidemiology literature. The claim is still true and valuable but the "surprising inversion" framing may be more 2020-level novelty than 2026-level novelty. - `us-healthspan-lifespan-gap-largest-globally-despite-highest-spending` references WHO data "2000-2019" in the body, while the description says "WHO data 2000-2021". Minor inconsistency in date range that should be resolved. - The `cvd-stagnation-reversed-racial-health-convergence` file appears in the existing domain (not in this PR's changes) but is referenced by new claims — confirm it exists and is correctly titled. --- ## What This PR Does Well The CVD/hypertension epidemiology cluster, despite the duplication issues, builds a genuinely important cross-claim argument: structural bifurcation (acute ischemia improving while chronic metabolic disease worsens), all-income-level stagnation (ruling out poverty explanation), life-expectancy impact quantification (3-11x the opioid effect), and UPF as a mechanistic driver. These claims together make a stronger argument than any single claim does. The regulatory rollback cluster is similarly well-structured: the MAUDE gap claims establish the surveillance failure, the EU/US/UK deregulation claims establish the policy failure, and the synthesis claim shows they're happening simultaneously. Good epistemic architecture overall. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Two new hypertension claims substantially duplicate existing claims (`hypertensive-disease-mortality-doubled` and `us-heart-failure-mortality-reversed`) with identical statistics. One confidence level needs downgrade (`multi-agent-65x` from `proven` to `likely`). One title overstates mechanism certainty (`upf-driven-chronic-inflammation`). The Lords Committee entity is incorrectly placed in `supports` field of the convergence claim. Missing wiki link between UPF inflammation and semaglutide anti-inflammatory claims. Other concerns are minor. Core epistemic architecture of the clusters is sound; the duplications are the primary blocker. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 09:02:20 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2492

Branch: reweave/2026-04-07
Scope: 30 files — 22 health claims, 6 space-development claims, 1 grand-strategy claim, 1 entity file

Duplicate / Near-Duplicate Issues (request changes)

Within-PR duplicates

1. SBSP/ODC — two files, one claim. orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md (experimental) and space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md (likely) make the same argument — Aetherflux's dual-use architecture, ODC as revenue bridge to SBSP, same sun-synchronous orbit requirements. Different sources (Galactic Brain announcement vs TechCrunch Series A) but identical thesis. Merge into one claim or differentiate their scope clearly.

2. FDA MAUDE — two files, one claim. fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md (Handley et al. 2024, 429 reports) and fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md (Babic et al. 2025, 943 events). Both say MAUDE can't track AI harm due to structural design gaps. The Babic study extends Handley's work. These should be one claim with both studies as evidence.

3. Regulatory deregulation cluster — three claims, substantial overlap. regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md, regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md, and regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md all cover the same Q4 2025–Q1 2026 EU/US deregulation window. The first focuses on temporal coincidence (FDA + ECRI same month), the second on the rollback itself, the third on the EU Commission–WHO epistemic split. The "institutional epistemic divergence" angle is genuinely distinct; the other two should merge or one should subsume the other.

Duplicates with existing KB

4. Hypertension — triple coverage. hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md (new, rated "proven") duplicates two existing claims:

  • hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md (existing, rated "likely")
  • hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md (existing, rated "proven")

All three use AHA/JACC data showing hypertension mortality doubled and became the #1 contributing CVD cause by 2022. The new claim adds no evidence the existing two don't already contain. Enrich the existing claims instead.

Confidence Calibration

multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md — rated "proven" from a single study. Mount Sinai's study is peer-reviewed but one institution, one architecture, one workload distribution. "Likely" fits better. "Proven" implies replication.

us-healthcare-ranks-last-among-peer-nations-despite-highest-spending.md — rated "proven." Appropriate — Commonwealth Fund Mirror Mirror is well-established, multi-year, multi-metric.

breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md — rated "speculative." Correct. A single investor signal doesn't validate a technology category.

Broken Wiki Links

50+ broken wiki links across the PR. Nearly every claim references files by prose title (e.g., [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model...]]) but the actual filenames use different slugs with spaces or truncations. This fails quality gate criterion 8 (wiki links resolve to real files).

Systemic issue — likely a tooling/convention mismatch rather than per-claim negligence. Recommend a batch fix: either normalize link format to match filenames, or create redirects/aliases. This alone would justify request_changes, but it's fixable mechanically.

Cross-Domain Connections Worth Noting

CVD causal chain is strong and well-constructed. UPF → chronic inflammation (REGARDS cohort) → incident hypertension → CVD mortality stagnation → healthspan decline despite lifespan recovery. Six claims in this PR build a coherent mechanistic story from dietary input to population-level outcome. This is exactly the kind of multi-layer evidence chain the KB should build. The UPF–inflammation–hypertension pathway (ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md) is the strongest new addition — prospective cohort, dose-response, mechanistic biomarkers.

Clinical AI regulatory convergence parallels AI weapons governance. The UK/EU/US adoption-acceleration convergence (uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md) has structural parallels with the grand-strategy claim about AI weapons governance tractability stratifying by strategic utility. Both show that governance tractability depends on the commercial/strategic value of the thing being governed — high-value applications resist regulation regardless of safety evidence. This cross-domain connection should be made explicit.

CLD Phase 2 freeze claims add genuine value. policy-driven-funding-freezes-can-be-as-damaging-to-commercial-space-timelines-as-technical-delays.md and phase-2-funding-freeze-disproportionately-harms-design-phase-programs-dependent-on-nasa-capital-for-manufacturing-transition.md are well-scoped, complementary (one general principle, one specific application), and extend the commercial station narrative with a policy-risk dimension the KB was missing.

Other Notes

  • Entity file (entities/health/uk-house-of-lords-science-technology-committee.md) is clean and well-structured. Good addition.
  • The human-in-the-loop claim filename has spaces instead of hyphens — inconsistent with convention and will break references. Should be slugified.
  • commercial space stations filename also has spaces — same issue.
  • Cipla dual-role claim is genuinely novel — portfolio hedge strategy for bifurcated markets is a distinct analytical frame not present in existing GLP-1 claims. Good addition.
  • Healthspan claims (us-healthspan-declining-while-lifespan-recovers-creating-divergence.md and us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md) are well-differentiated from each other (trend vs. comparative ranking) and from existing KB content. Both add value.

Verdict: request_changes
Model: opus
Summary: Strong thematic clusters (CVD causal chain, clinical AI regulatory convergence, space policy risk) with genuine analytical value, but 3 within-PR near-duplicate pairs, 1 KB duplicate (hypertension triple-coverage), confidence miscalibration on multi-agent AI claim, 50+ broken wiki links, and 2 filenames with spaces need resolution before merge.

# Leo Cross-Domain Review — PR #2492 **Branch:** reweave/2026-04-07 **Scope:** 30 files — 22 health claims, 6 space-development claims, 1 grand-strategy claim, 1 entity file --- ## Duplicate / Near-Duplicate Issues (request changes) ### Within-PR duplicates **1. SBSP/ODC — two files, one claim.** `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` (experimental) and `space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` (likely) make the same argument — Aetherflux's dual-use architecture, ODC as revenue bridge to SBSP, same sun-synchronous orbit requirements. Different sources (Galactic Brain announcement vs TechCrunch Series A) but identical thesis. Merge into one claim or differentiate their scope clearly. **2. FDA MAUDE — two files, one claim.** `fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md` (Handley et al. 2024, 429 reports) and `fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md` (Babic et al. 2025, 943 events). Both say MAUDE can't track AI harm due to structural design gaps. The Babic study extends Handley's work. These should be one claim with both studies as evidence. **3. Regulatory deregulation cluster — three claims, substantial overlap.** `regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md`, `regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md`, and `regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md` all cover the same Q4 2025–Q1 2026 EU/US deregulation window. The first focuses on temporal coincidence (FDA + ECRI same month), the second on the rollback itself, the third on the EU Commission–WHO epistemic split. The "institutional epistemic divergence" angle is genuinely distinct; the other two should merge or one should subsume the other. ### Duplicates with existing KB **4. Hypertension — triple coverage.** `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` (new, rated "proven") duplicates two existing claims: - `hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md` (existing, rated "likely") - `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md` (existing, rated "proven") All three use AHA/JACC data showing hypertension mortality doubled and became the #1 contributing CVD cause by 2022. The new claim adds no evidence the existing two don't already contain. Enrich the existing claims instead. --- ## Confidence Calibration **`multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md` — rated "proven" from a single study.** Mount Sinai's study is peer-reviewed but one institution, one architecture, one workload distribution. "Likely" fits better. "Proven" implies replication. **`us-healthcare-ranks-last-among-peer-nations-despite-highest-spending.md` — rated "proven."** Appropriate — Commonwealth Fund Mirror Mirror is well-established, multi-year, multi-metric. **`breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md` — rated "speculative."** Correct. A single investor signal doesn't validate a technology category. --- ## Broken Wiki Links **50+ broken wiki links across the PR.** Nearly every claim references files by prose title (e.g., `[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model...]]`) but the actual filenames use different slugs with spaces or truncations. This fails quality gate criterion 8 (wiki links resolve to real files). Systemic issue — likely a tooling/convention mismatch rather than per-claim negligence. Recommend a batch fix: either normalize link format to match filenames, or create redirects/aliases. This alone would justify request_changes, but it's fixable mechanically. --- ## Cross-Domain Connections Worth Noting **CVD causal chain is strong and well-constructed.** UPF → chronic inflammation (REGARDS cohort) → incident hypertension → CVD mortality stagnation → healthspan decline despite lifespan recovery. Six claims in this PR build a coherent mechanistic story from dietary input to population-level outcome. This is exactly the kind of multi-layer evidence chain the KB should build. The UPF–inflammation–hypertension pathway (`ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md`) is the strongest new addition — prospective cohort, dose-response, mechanistic biomarkers. **Clinical AI regulatory convergence parallels AI weapons governance.** The UK/EU/US adoption-acceleration convergence (`uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md`) has structural parallels with the grand-strategy claim about AI weapons governance tractability stratifying by strategic utility. Both show that governance tractability depends on the commercial/strategic value of the thing being governed — high-value applications resist regulation regardless of safety evidence. This cross-domain connection should be made explicit. **CLD Phase 2 freeze claims add genuine value.** `policy-driven-funding-freezes-can-be-as-damaging-to-commercial-space-timelines-as-technical-delays.md` and `phase-2-funding-freeze-disproportionately-harms-design-phase-programs-dependent-on-nasa-capital-for-manufacturing-transition.md` are well-scoped, complementary (one general principle, one specific application), and extend the commercial station narrative with a policy-risk dimension the KB was missing. --- ## Other Notes - **Entity file** (`entities/health/uk-house-of-lords-science-technology-committee.md`) is clean and well-structured. Good addition. - **The `human-in-the-loop` claim filename has spaces instead of hyphens** — inconsistent with convention and will break references. Should be slugified. - **`commercial space stations` filename also has spaces** — same issue. - **Cipla dual-role claim** is genuinely novel — portfolio hedge strategy for bifurcated markets is a distinct analytical frame not present in existing GLP-1 claims. Good addition. - **Healthspan claims** (`us-healthspan-declining-while-lifespan-recovers-creating-divergence.md` and `us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md`) are well-differentiated from each other (trend vs. comparative ranking) and from existing KB content. Both add value. --- **Verdict:** request_changes **Model:** opus **Summary:** Strong thematic clusters (CVD causal chain, clinical AI regulatory convergence, space policy risk) with genuine analytical value, but 3 within-PR near-duplicate pairs, 1 KB duplicate (hypertension triple-coverage), confidence miscalibration on multi-agent AI claim, 50+ broken wiki links, and 2 filenames with spaces need resolution before merge. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 09:02:20 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 09:13:42 +00:00
m3taversal commented 2026-04-07 09:13:42 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2492
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?